Weinhaus A J, Bhagroo N V, Brelje T C, Sorenson R L
Department of Cell Biology and Neuroanatomy, University of Minnesota Medical School, Minneapolis 55455-0303, USA.
Diabetes. 1998 Sep;47(9):1426-35. doi: 10.2337/diabetes.47.9.1426.
Islets undergo a number of upregulatory changes to meet the increased demand for insulin during pregnancy, including an increase in glucose-stimulated insulin secretion with a reduction in the stimulation threshold. Treatment with the lactogenic hormone prolactin (PRL) in vitro has been shown to induce changes in islets similar to those observed during pregnancy. We examined cAMP production in islets treated with PRL to determine if changes in cAMP are involved in the upregulation of insulin secretion. Insulin secretion and cAMP concentrations were measured from islets in response to a suprathreshold (6.8 mmol/l) or high (16.8 mmol/l) glucose concentration in the presence of the phosphodiesterase inhibitor isobutylmethylxanthine. Insulin secretion increased by 2.1-, 5.0-, and 5.9-fold at the suprathreshold glucose concentration and by 1.6-, 2.3-, and 2.9-fold at the higher glucose concentration after 1, 3, and 5 days of PRL treatment, respectively. After a similar pattern, cAMP metabolism increased by 1.2-, 1.6-, and 2.1-fold at the suprathreshold glucose concentration and by 1.2-, 1.7-, and 2.2-fold at the high glucose concentration after 1, 3, and 5 days of PRL treatment, respectively. The similar increases in insulin secretion and cAMP concentration suggest that changes in cAMP metabolism are involved in lactogen-induced upregulation of insulin secretion. To gain additional insight into the role of cAMP in the upregulation of islet function after lactogen treatment, we examined the relationship between changes in cAMP concentration and insulin secretion. Under all conditions (differing glucose concentrations and time periods), the increase in insulin release was directly proportional to the increase in cAMP. Thus increased glucose-stimulated insulin secretion from lactogen-treated islets could be accounted for by increased generation of cAMP and did not appear to require any further specific changes in intracellular processes mediated by cAMP. Because the PRL receptor is not directly involved in cAMP metabolism, the lactogen-induced increase in cAMP was most likely due to the increase in glucose metabolism that we have previously demonstrated in PRL-treated islets and in islets during pregnancy.
在孕期,胰岛会经历一系列上调性变化以满足对胰岛素日益增加的需求,包括葡萄糖刺激的胰岛素分泌增加以及刺激阈值降低。体外使用催乳素(PRL)进行处理已显示可诱导胰岛发生类似于孕期所观察到的变化。我们检测了经PRL处理的胰岛中cAMP的产生情况,以确定cAMP的变化是否参与胰岛素分泌的上调。在磷酸二酯酶抑制剂异丁基甲基黄嘌呤存在的情况下,测量胰岛对阈上(6.8 mmol/L)或高(16.8 mmol/L)葡萄糖浓度的反应时的胰岛素分泌和cAMP浓度。PRL处理1、3和5天后,在阈上葡萄糖浓度下胰岛素分泌分别增加了2.1倍、5.0倍和5.9倍,在较高葡萄糖浓度下分别增加了1.6倍、2.3倍和2.9倍。呈现类似模式的是,PRL处理1、3和5天后,在阈上葡萄糖浓度下cAMP代谢分别增加了1.2倍、1.6倍和2.1倍,在高葡萄糖浓度下分别增加了1.2倍、1.7倍和2.2倍。胰岛素分泌和cAMP浓度的类似增加表明,cAMP代谢的变化参与了催乳素诱导的胰岛素分泌上调。为了进一步深入了解cAMP在催乳素处理后胰岛功能上调中的作用,我们检测了cAMP浓度变化与胰岛素分泌之间的关系。在所有条件下(不同葡萄糖浓度和时间段),胰岛素释放的增加与cAMP的增加成正比。因此,催乳素处理的胰岛中葡萄糖刺激的胰岛素分泌增加可能是由于cAMP生成增加所致,并且似乎不需要cAMP介导的细胞内过程有任何进一步的特定变化。由于PRL受体不直接参与cAMP代谢,催乳素诱导的cAMP增加很可能是由于我们先前在PRL处理的胰岛以及孕期胰岛中所证明的葡萄糖代谢增加。